Recombinant albumins containing additional peptide sequences smaller than barbourin retain the ability of barbourin-albumin to inhibit platelet aggregation

Thrombosis and Haemostasis

Volumn 93, Issue 5, 2005, Pages 914-921

  Sheffield, William P ^a,b   Wilson, Brianna ^a   Eltringham Smith, Louise J ^a   Gataiance, Sharon ^a   Bhakta, Varsha ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

Author keywords

Aggregation; Albumin; Disintegrin; Peptides; Platelets

Indexed keywords

ADENOSINE DIPHOSPHATE; BARBOURIN; BARBOURIN[41-54]; DISINTEGRIN; HISTIDINE; HYBRID PROTEIN; INTEGRIN; LEUCYLPROLYLSERYLPROLYLGLYCYLASPARTYLTRYPTOPHYLARGININE; OLIGONUCLEOTIDE; PEPTIDE; PLASMA PROTEIN; PROTEIN ANTIBODY; PROTEIN BLAH 6; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VALYLCYSTEINYLARGINYLGLYCYLASPARTYLTRYPTOPHYLPROLYLCYSTEINE; VALYLCYSTEINYLLYSYLGLYCYLASPARTYLTRYPTOPHYLPROLYLCYSTEINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ARTICLE; CELL LYSATE; CONTROLLED STUDY; IMMUNOGENICITY; IMMUNOPRECIPITATION; MALE; NONHUMAN; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; RABBIT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA;

ADENOSINE DIPHOSPHATE; ALBUMINS; AMINO ACID SEQUENCE; ANIMALS; CROTALID VENOMS; DNA; HUMANS; IMMUNOPRECIPITATION; INHIBITORY CONCENTRATION 50; MALE; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES; PEPTIDES; PICHIA; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RABBITS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 18844423300     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-08-0554     Document Type: Article

References (33)

1. Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs 2002; 1: 273-88.
2. Weiss HJ. Flow-related platelet deposition on sub-endothelium. Thromb Haemost 1995; 74: 117-22.
3. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-87.
4. Fullard JF. The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis. Curr Pharm Des 2004;10: 1567-76.
5. Plow EF, Byzova T. The biology of glycoprotein IIb-IIIa. Coron Artery Dis 1999; 10: 547-51.
6. Hanson J, de Leval X, David JL, et al. Progress in the field of GPIIb/IIIa antagonists. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 157-67.
7. Rosove MH. Platelet glycoprotein IIb/IIIa inhibitors. Best Pract Res Clin Haematol 2004; 17: 65-76.
8. Scarborough RM, Rose JW Hsu MA, et al. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem 1991; 266: 9359-62.
9. Scarborough RM, Naughton MA, Teng W, et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993; 268: 1066-73.
10. Scarborough RM. Development of eptifibatide. Am Heart J 1999; 138: 1093-104.
11. Syed S, Schuyler PD, Kulczycky M, et al. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood 1997; 89: 3243-52.
12. Sheffield WP, Smith IJ, Syed S, et al. Prolonged in vivo anticoagulant activity of a hirudin-albumin fusion protein secreted from Pichia pastoris. Blood Coagul Fibrinolysis 2001; 12: 433-43.
13. Marques JA, George JK, Smith IJ, et al. A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro. Thromb Haemost 2001; 86: 902-8.
14. McCollam PL, Foster DA, Riesmeyer JS. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Health Syst Pharm 2003; 60: 1251-6.
15. Leung VW, Sunderji R, Zed PJ, et al. Switching from abciximab to eptifibatide for percutaneous coronary interventions: a local analysis (SWAP study). Can J Cardiol 2003; 19: 809-14.
16. Kobayashi K, Nakamura N, Sumi A, et al. The development of recombinant human serum albumin. Ther Apher 1998; 2: 257-62.
17. McCurdy TR, Gataiance S, Eltringham-Smith LJ, et al. A covalently linked recombinant albumin dimer is more rapidly cleared in vivo than are wild-type and mutant C34A albumin. J Lab Clin Med 2004; 143: 115-24.
18. Kelton JG, Smith JW, Horsewood P, et al. Gova/b alloantigen system on human platelets. Blood 1990; 75: 2172-6.
19. Smith JW, Kelton JG, Horsewood P, et al. Platelet specific alloantigens on the platelet glycoprotein Ia/IIa complex. Br J Haematol 1989;72: 534-8.
20. Bhakta V, Begbie ME, Gupta A, et al. Heparin cofactor II is more sensitive than antithrombin to secretory impairment arising from mutations introduced into its carboxy-terminal region. Thromb Res 2004; 113: 163-73.
21. Markwell MA. A new solid-state reagent to iodinate proteins. I. Conditions for the efficient labeling of antiserum. Anal Biochem 1982; 125: 427-32.
22. Sheffield WP, Blajchman MA. Amino acid substitutions of the P2 residue of human antithrombin that either enhance or impair function. Thromb Res 1994; 75: 293-305.
23. Moriguchi A, Aoki T, Mihara K, et al. Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban. J Pharmacol Exp Ther 2004; 308: 1094-101.
24. Hayashi Y, Katada J, Sato Y, et al. Discovery and structure--activity relationship studies of a novel and specific peptide motif, Pro-X-X-X-Asp-X, as a platelet fibrinogen receptor antagonist. Bioorg Med Chem 1998; 6: 355-64.
25. Brake AJ, Merryweather JP, Coit DG, et al. Alpha-factor-directed synthesis and secretion of mature foreign proteins in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 1984; 81: 4642-6.
26. Lorenz TJ, Macdonald F, Kitt MM. Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIa. Clin Ther 1999; 21: 128-37.
27. Swenson S, Costa F, Minea R, et al. Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. Mol Cancer Ther 2004; 3: 499-511.
28. Curtis BR, Swyers J, Divgi A, et al. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002; 99: 2054-9.
29. Kereiakes DJ, Runyon JP, Broderick TM, et al. IIb's are not IIb's. Am J Cardiol 2000; 85: 23C-31C.
30. Shin J, Hong SY, Chung K, et al. Solution structure of a novel disintegrin, salmosin, from Agkistrondon halys venom. Biochemistry 2003; 42: 14408-15.
31. Smith KJ, Jaseja M, Lu X, et al. Three-dimensional structure of the RGD-containing snake toxin albolabrin in solution, based on 1H NMR spectroscopy and simulated annealing calculations. Int J Pept Protein Res 1996; 48: 220-8.
32. Huang TF. What have snakes taught us about integrins? Cell Mol Life Sci 1998; 54: 527-40.
33. Harfenist EJ, Packham MA, Mustard JF. Effects of the cell adhesion peptide, Arg-Gly-Asp-Ser, on responses of washed platelets from humans, rabbits, and rats. Blood 1988; 71: 132-6.